Jubilant Pharmova Limited Q4 results show revenue rise from 1561.98 to 1682.45 crores, a 7.71% increase in growth. EPS also dropped from ₹-0.98 to ₹-6.15, down by 527.55%.
First, Let’s Begin with Quarter-on-Quarter Basis:
Jubilant Pharmova Ltd shared its Q4 results on Monday. They earned 1682.45 crores in revenue this quarter, but that’s higher than the 1561.98 crores they made last quarter. The company’s growth increased by 7.71 percent when comparing the two quarters.
In terms of profits, the company’s PAT (Profit After Tax) for this quarter was -97.84 crores, down from -15.67 crores in the previous quarter. Their quarter-to-quarter growth declined by 524.38 percent.
The company’s EPS (Earnings Per Share) this quarter is ₹-6.15, which is a decrease of 527.55% from the ₹-0.98 EPS in the previous quarter.
Also read: ☞ ” Natco Pharma Q4FY23 Results: Consolidated PAT Rose to Rs 275.8 Cr “
Now, Let’s Analyze the Results on a Year-over-Year Basis:
The company made a total revenue of 6320.06 crores this year (2023), which is 2.91 percent higher than last year’s total revenue of 6141.45 crores.
This year’s PAT (Profit After Tax) is -60.98 crores, which is also 85.27% lower than last year’s PAT of 413.94 crores.
The EPS (Earnings Per Share) for this year is ₹-3.83, which is 85.27% less than the EPS of ₹26.00 earned last year.
Jubilant Pharmova Share Dividend Announcement / Record Date:
Not related to distributing a portion of a company’s earnings to shareholders in the form of cash or stock dividends. ( No Dividend Payout )
About Jubilant Pharmova:
Jubilant Life Sciences Limited is a global pharmaceutical and life sciences company that operates across various sectors. The company is involved in the manufacturing and supply of active pharmaceutical ingredients (APIs), solid dosage formulations, radiopharmaceuticals, allergy therapy products, advanced intermediates, fine ingredients, crop science ingredients, life science chemicals, and nutritional products. In addition, Jubilant Life Sciences offers services such as contract manufacturing of sterile injectables and drug discovery solutions. The company’s distinctive strength lies in its wide range of offerings in the pharmaceutical and life sciences domain, including products and services.
Download the Full PDF of Q4 Results: Click Here
For more of the Latest News, Click Here
One thought on “Jubilant Pharmova Q4FY23 Results: Consolidated Loss of Rs 97.84 Cr”